The estimated Net Worth of Benjamin Hickey is at least $9.1 Million dollars as of 16 January 2024. Mr Hickey owns over 1,597 units of Mirati Therapeutics Inc stock worth over $6,869,544 and over the last 6 years he sold MRTX stock worth over $1,427,617. In addition, he makes $798,317 as Chief Commercial Officer at Mirati Therapeutics Inc.
Mr has made over 11 trades of the Mirati Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,597 units of MRTX stock worth $94,255 on 16 January 2024.
The largest trade he's ever made was exercising 20,216 units of Mirati Therapeutics Inc stock on 1 October 2019 worth over $1,186,679. On average, Mr trades about 1,742 units every 68 days since 2018. As of 16 January 2024 he still owns at least 117,028 units of Mirati Therapeutics Inc stock.
You can see the complete history of Mr Hickey stock trades at the bottom of the page.
Benjamin J. Hickey M.B.A. is the Chief Commercial Officer at Mirati Therapeutics Inc.
As the Chief Commercial Officer of Mirati Therapeutics Inc, the total compensation of Mr A at Mirati Therapeutics Inc is $798,317. There are 6 executives at Mirati Therapeutics Inc getting paid more, with Charles Baum having the highest compensation of $8,484,390.
Mr A is 46, he's been the Chief Commercial Officer of Mirati Therapeutics Inc since . There are 16 older and 3 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.
Benjamin's mailing address filed with the SEC is BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NJ, 08543.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza..., and Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: